A STUDY ON THE CLINICAL CHARACTERISTICS AND TREATMENT ADHERENCE IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE AT LE VAN THINH HOSPITAL
Main Article Content
Abstract
Objective: To investigate clinical and paraclinical characteristics, treatment adherence rates, and related factors in patients with gastroesophageal reflux disease at Le Van Thinh Hospital.
Methods: A cross-sectional descriptive study was conducted on 303 outpatients aged 18 and older diagnosed with gastroesophageal reflux disease. Data on demographics, clinical and paraclinical characteristics, and treatment adherence using the MMAS-8 scale were collected. Multivariate logistic regression analysis was used to identify factors associated with adherence.
Results: Females predominated (56.4%) with a mean age of 47.8 years. Clinically, heartburn accounted for 59.7% and regurgitation for 48.8%. Endoscopically, non-erosive reflux disease accounted for the majority (74.3%). The overall treatment adherence rate (medium and high) was 64%. 4 independent factors significantly reduced treatment adherence: increased total daily pill count (OR = 0.79; p = 0.002), presence of anxiety/depression (OR = 0.49; p = 0.028), concomitant other gastrointestinal diseases (OR = 0.48; p = 0.021), and presence of regurgitation symptoms (OR = 0.43; p = 0.015).
Conclusion: The majority of patients presented with typical clinical manifestations, although most cases were classified as non-erosive reflux disease. Treatment adherence was generally moderate. Optimizing pill burden and attending to mental health are necessary to improve treatment efficacy.
Article Details
Keywords
Gastroesophageal reflux disease, GERD, treatment adherence, MMAS-8.
References
[2] Wiesner A, Zwolińska-Wcisło M, Paśko P. Effect of food and dosing regimen on safety and efficacy of proton pump inhibitors therapy - A literature review. Int J Environ Res Public Health, 2021, 18 (7): 3527. doi: 10.3390/ijerph18073527.
[3] Hoàng Thy Nhạc Vũ, Trần Văn Khanh. Đặc điểm mô hình bệnh tật Bệnh viện Lê Văn Thịnh giai đoạn 2018-2023. Tạp chí Y học cộng đồng, 2024, 65 (CĐ6): 24-33. doi: 10.52163/yhc.v65iCD6.1349.
[4] Lê Thị Thanh Thủy, Lê Thị Xuân Thảo. Tuân thủ điều trị tiệt trừ Helicobacter pylori ở bệnh nhân viêm loét dạ dày-tá tràng. Tạp chí Y học thành phố Hồ Chí Minh, 2017, 21 (2): 251-258.
[5] Xie F, Yang B, Yan Z et al. Global temporal trends and projections of gastroesophageal reflux disease prevalence: Age-period-cohort analysis 2021. PLoS One, 2025, 20 (11): e0334396. doi: 10.1371/journal.pone.0334396.
[6] Quach D.T, Phan B.T. A long duration of reflux symptoms is the predominant risk factor for depression in Vietnamese patients with gastroesophageal reflux disease. Neuropsychiatr Dis Treat, 2022, 18: 2141-2150. doi: 10.2147/NDT.S381892.
[7] Wang H, Qu Y, Lin Y et al. Helicobacter pylori infection and eradication in relation to gastroesophageal reflux disease. J Gastroenterol Hepatol, 2025, 40 (10): 2391-2401. doi: 10.1111/jgh.70009.
[8] Kishor R, Kumari S et al. An assessment of treatment compliance using the Morisky scale-8 tool in adult hypertensive patients of Eastern India. J Family Med Prim Care, 2024, 13 (3): 924-931. doi: 10.4103/jfmpc.jfmpc_1416_23.
[9] Puig-Moltó M, Lumbreras B, López-Pintor E. Improving proton-pump inhibitor adherence intervention between primary care and community pharmacies: A pre-post intervention study. Patient Prefer Adherence, 2024, 18: 2569-2580. doi: 10.2147/PPA.S485307.
[10] He M, Wang Q et al. Association between psychosocial disorders and gastroesophageal reflux disease: A systematic review and meta-analysis. J Neurogastroenterol Motil, 2022, 28 (2): 212-221. doi: 10.5056/jnm21044.
[11] Cassell B, Gyawali C.P et al. Beliefs about GI medications and adherence to pharmacotherapy in functional GI disorder outpatients. Am J Gastroenterol, 2015, 110 (10): 1382-1387. doi: 10.1038/ajg.2015.132.
[12] Mermelstein J, Chait Mermelstein A, Chait M.M. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol, 2018, 11: 119-134. doi: 10.2147/CEG.S121056.